- Home
- NMRA vs BBOT Comparison
NMRA vs BBOT Comparison
Compare NMRA & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRA | BBOT |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | 92 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.0M | 632.1M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMRA | BBOT |
|---|---|---|
| Price | $1.90 | $8.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $7.50 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 1.5M | 369.3K |
| Earning Date | 05-07-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $7.60 |
| 52 Week High | $3.65 | $14.87 |
Technical Indicators
Market Signals| Indicator | NMRA | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 45.31 |
| Support Level | $1.81 | $8.08 |
| Resistance Level | $2.22 | $12.36 |
| Average True Range (ATR) | 0.22 | 0.55 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 15.32 | 39.13 |
Price Performance
Historical ComparisonAbout NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.